Study of Patients With Acute Renal Failure on CVVH
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 6/15/2016 |
| Start Date: | February 2005 |
| End Date: | March 2010 |
The Role of Hemodynamics, Cytokine Response, and Modulators of Apoptosis on Urine Output in Patients With Acute Renal Failure on CVVH
Acute kidney failure is common in children in the Pediatric Intensive Care Unit (PICU). You
are being asked to participate in this study because your child is being treated for kidney
failure with continuous veno-venous hemofiltration (CVVH). CVVH is a continuous, gentle form
of removing excess fluids and small wastes from the blood, similar to kidney dialysis
(artificial kidney). It is an accepted therapy for temporary support of kidney failure. In
some patients with acute kidney failure, beginning CVVH is followed by a temporary decrease
of urine output. The reason why this happens is currently unknown. The purpose of this study
is to determine why this happens.
are being asked to participate in this study because your child is being treated for kidney
failure with continuous veno-venous hemofiltration (CVVH). CVVH is a continuous, gentle form
of removing excess fluids and small wastes from the blood, similar to kidney dialysis
(artificial kidney). It is an accepted therapy for temporary support of kidney failure. In
some patients with acute kidney failure, beginning CVVH is followed by a temporary decrease
of urine output. The reason why this happens is currently unknown. The purpose of this study
is to determine why this happens.
Acute renal failure is common in children in the pediatric intensive care unit. Renal
replacement therapies such as peritoneal dialysis (PD), intermittent hemodialysis (IHD), and
continuous venovenous hemofiltration (CVVH) have been used in the management of acute renal
failure. CVVH is becoming increasingly utilized in pediatric acute renal failure. However,
in patients who have acute renal failure, the institution of CVVH is often followed by a
progression to oliguria or anuria. The underlying pathophysiology of this change is unknown.
We believe that this progression is influenced by changes in the renin-angiotensin axis,
cytokine response, and other modifiers of renal hemodynamics. By serially measuring
components of those systems, this study will attempt to elucidate the pathophysiology of the
decreased urine output seen with institution of CVVH. Once this process is understood,
future studies should focus on prevention and treatment of this complication.
General Hypothesis
The decrease in urine output seen after the initiation of CVVH is associated with increased
angiotensin converting enzyme (ACE) levels, increased renin activity, increased angiotensin
II levels, increased atrial naturetic peptide (ANP) levels, increased endothelin-1 levels,
increased arginine vasopressin (AVP) levels, and alterations of cytokine levels and
modulators of apoptosis.
replacement therapies such as peritoneal dialysis (PD), intermittent hemodialysis (IHD), and
continuous venovenous hemofiltration (CVVH) have been used in the management of acute renal
failure. CVVH is becoming increasingly utilized in pediatric acute renal failure. However,
in patients who have acute renal failure, the institution of CVVH is often followed by a
progression to oliguria or anuria. The underlying pathophysiology of this change is unknown.
We believe that this progression is influenced by changes in the renin-angiotensin axis,
cytokine response, and other modifiers of renal hemodynamics. By serially measuring
components of those systems, this study will attempt to elucidate the pathophysiology of the
decreased urine output seen with institution of CVVH. Once this process is understood,
future studies should focus on prevention and treatment of this complication.
General Hypothesis
The decrease in urine output seen after the initiation of CVVH is associated with increased
angiotensin converting enzyme (ACE) levels, increased renin activity, increased angiotensin
II levels, increased atrial naturetic peptide (ANP) levels, increased endothelin-1 levels,
increased arginine vasopressin (AVP) levels, and alterations of cytokine levels and
modulators of apoptosis.
Inclusion Criteria:
The general goal of patient selection is to enroll all children for whom CVVH is
instituted.
Inclusion criteria:
Age
- 6 months -18 years old
- Patients less than 6 months of age on ECMO (addendum #1)
Indication for CVVH: including, but not limited to :
- Acute Renal Failure
- Oliguria
- Anuria
- Hyperkalemia
- Severe acidemia
- Azotemia
- Pulmonary Edema
- Uremic complications
- Severe electrolyte abnormalities
- Drug overdose with a filterable toxin
- Anasarca
- Rhabdomyolysis
Exclusion Criteria:
- Age
- Less than 6 months old (unless on ECMO)
- Greater than 18 years old Weight
- Less than 5 kilograms (unless ON ECMO) Location
- Cardiac Intensive Care Unit
- Neonatal Intensive Care Unit
Non-adherence:
Inability or unwillingness of the legal guardian to provide consent or inability or
unwillingness of the child to provide assent
We found this trial at
1
site
Click here to add this to my saved trials
